Intelligent Bio Solutions shipped the first batch of its fingerprinting drug screening readers manufactured by Syrma Johari MedTech, marking the initial deployment under the December 2025 partnership. The collaboration provides quadruple the prior reader output, with ISO 13485 and MDSAP compliance, and positions the company to meet rising demand in the U.K. and Europe.

The Syrma Johari partnership is on track to deliver over 40% annual production cost savings, translating to an anticipated 20-percentage-point boost to gross margins. This cost efficiency is expected to enhance profitability as production scales and larger order volumes reduce per-unit expenses.

INBS has doubled its in-house lateral flow test strip production capacity through advanced manufacturing equipment, improving vertical integration and component control. The expanded output accelerates R&D by providing greater inventory for testing and enables development of multi-analyte panels for diverse customer segments.

With core operations established in Europe, the company is preparing to enter the U.S. market later in 2026 beyond the Forensic Use Only category. The scaled manufacturing engine and strengthened commercial readiness support regulatory submissions and anticipated demand in safety-critical industries such as construction and transportation.